



Final Appraisal Recommendation
Advice No: 1517 – July 2017

Triamcinolone hexacetonide 20 mg/ml suspension for injection

Limited submission by Intrapharm Laboratories Ltd

Recommendation of AWMSG

Triamcinolone hexacetonide is recommended as an option for use within NHS Wales for the treatment of juvenile idiopathic arthritis.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2527), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Intrapharm Laboratories Ltd
Date of first issue	July 2017
Last reviewed	August 2020

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1517:
Triamcinolone hexacetonide 20 mg/ml suspension for injection July 2017